來源:[1] 默克在其搖錢樹專利懸崖期到來之前獲得一項關鍵批准 (https://finance.yahoo.com/m/cd506ba7-c40c-3fd ...)[2] 隨著獨佔期即將結束,默克贏得Keytruda皮下注射劑批准 - BioSpace (https://www.biospace.com/article/as-exclusivi ...)[3] 默克的Keytruda Qlex:競爭差異化和腫瘤市場擴張的戰略飛躍 - AInvest (https://vertexaisearch.cloud.google.com/groun ...)